JP2022546807A5 - - Google Patents
Info
- Publication number
- JP2022546807A5 JP2022546807A5 JP2022513249A JP2022513249A JP2022546807A5 JP 2022546807 A5 JP2022546807 A5 JP 2022546807A5 JP 2022513249 A JP2022513249 A JP 2022513249A JP 2022513249 A JP2022513249 A JP 2022513249A JP 2022546807 A5 JP2022546807 A5 JP 2022546807A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- independently
- aliphatic
- formula
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019903263 | 2019-09-04 | ||
| AU2019903263A AU2019903263A0 (en) | 2019-09-04 | Cancer treatment | |
| AU2019904863A AU2019904863A0 (en) | 2019-12-20 | Cancer treatment (2) | |
| AU2019904863 | 2019-12-20 | ||
| PCT/AU2020/050936 WO2021042174A1 (en) | 2019-09-04 | 2020-09-04 | Cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026078263A Division JP2026129928A (ja) | 2019-09-04 | 2026-05-07 | 癌の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546807A JP2022546807A (ja) | 2022-11-09 |
| JP2022546807A5 true JP2022546807A5 (cg-RX-API-DMAC7.html) | 2023-09-11 |
| JP7862297B2 JP7862297B2 (ja) | 2026-05-19 |
Family
ID=74851931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513249A Active JP7862297B2 (ja) | 2019-09-04 | 2020-09-04 | 癌の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220347146A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025203A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7862297B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020343725B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021042174A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2811957C (en) | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| IL275360B2 (en) | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
| NZ783377A (en) | 2019-06-26 | 2026-03-27 | Ena Respiratory Pty Ltd | Pegylated novel molecules for agonising tlr2 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1861426A4 (en) * | 2005-02-08 | 2008-11-12 | Queensland Inst Med Res | IMMUNOGENOUS MOLECULES |
| GB0907989D0 (en) * | 2009-05-08 | 2009-06-24 | Hybrid Systems Ltd | Multivalent adjuvant display |
| CA2811957C (en) * | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| IN2014CN02581A (cg-RX-API-DMAC7.html) * | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
| US20170274068A1 (en) * | 2014-09-12 | 2017-09-28 | The University Of Melbourne | Immunological reagent |
| EP3328418A1 (en) * | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| AU2018241248B2 (en) * | 2017-03-31 | 2025-01-23 | Ena Respiratory Pty Ltd | Treatment of respiratory infection with a TLR2 agonist |
| IL275360B2 (en) * | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
| JP2022546806A (ja) * | 2019-09-04 | 2022-11-09 | アクセリア オンコロジー ピーティーワイ リミテッド | 癌免疫療法 |
-
2020
- 2020-09-04 WO PCT/AU2020/050936 patent/WO2021042174A1/en not_active Ceased
- 2020-09-04 US US17/640,714 patent/US20220347146A1/en active Pending
- 2020-09-04 JP JP2022513249A patent/JP7862297B2/ja active Active
- 2020-09-04 EP EP20859699.9A patent/EP4025203A4/en active Pending
- 2020-09-04 AU AU2020343725A patent/AU2020343725B2/en active Active